IPSC-HEPs: hepatotoxicity and drug metabolism by biotech and pharmaceutical companies. KU Leuven
Stem Cell and Developmental Biology, Switch Laboratory (VIB-KU Leuven), Laboratory of Virology and Chemotherapy (Rega Institute)
As a result of several finalized projects we developed a robust differentiation protocol for the generation of hepatic progeny from induced pluripotent stem cells (iPSCs) with drug metabolisation enzyme function in the 30 percent range of primary plated (12h) hepatocytes. Furthermore we can now maintain these cells for =/> 2 weeks, allowing for the first time repeated dose metabolisation and toxicity studies. We also developed a robust 384 ...